Neoadjuvant letrozole in postmenopausal estrogen and/or progesterone receptor positive breast cancer: a phase IIb/III trial to investigate optimal duration of preoperative endocrine therapy

Ute E Krainick-Strobel, Werner Lichtenegger, Diethelm Wallwiener, Augustinus H Tulusan, Fritz Jänicke, Gunther Bastert, Ludwig Kiesel, Birgit Wackwitz, Stefan Paepke, Ute E Krainick-Strobel, Werner Lichtenegger, Diethelm Wallwiener, Augustinus H Tulusan, Fritz Jänicke, Gunther Bastert, Ludwig Kiesel, Birgit Wackwitz, Stefan Paepke

Abstract

Background: In recent years, preoperative volume reduction of locally advanced breast cancers, resulting in higher rates of breast-conserving surgery (BCS), has become increasingly important also in postmenopausal women. Clinical interest has come to center on the third-generation nonsteroidal aromatase inhibitors (AIs), including letrozole, for such neoadjuvant endocrine treatment. This usually lasts 3-4 months and has been extended to up to 12 months, but optimal treatment duration has not been fully established.

Methods: This study was designed as a multicenter, open-label, single-arm, exploratory phase IIb/III clinical trial of letrozole 2.5 mg, one tablet daily, for 4-8 months. The primary objective was to investigate the effect of neoadjuvant treatment duration on tumor regression and BCS eligibility to identify optimal treatment duration. Tumor regression (by clinical examination, mammography, and ultrasound), shift towards BCS eligibility, and safety assessments were the main outcome measures. Standard parametric and nonparametric descriptive statistics were performed.

Results: Letrozole treatment was received by 32 of the enrolled 33 postmenopausal women (median (range): 67.0 (56-85) years) with unilateral, initially BCS-ineligible primary breast cancer (clinical stage > or = T2, N0, M0). Letrozole treatment duration in the modified intent-to-treat (ITT; required 4 months' letrozole treatment) analysis population (29 patients) was 4 months in 14 patients and > 4 months in 15 patients. The respective per-protocol (PP) subgroup sizes were 14 and 11. The majority of partial or complete responses were observed at 4 months, though some beneficial responses occurred during prolonged letrozole treatment. Compared with baseline, median tumor size in the ITT population was reduced by 62.5% at Month 4 and by 70.0% at final study visit (Individual End). Similarly, in the PP population, respective reductions were 64.0% and 67.0%. Whereas initially all patients were mastectomy candidates, letrozole treatment enabled BCS (lumpectomy) in 22 ITT (75.9%) and 18 PP (72.0%) patients.

Conclusion: Over half of patients become BCS-eligible within 4 months of preoperative letrozole treatment. While prolonged treatment for up to 8 months can result in further tumor volume reduction in some patients, there is no clear optimum for treatment duration. Letrozole has a favorable overall safety and tolerability profile.

Trial registration: ClinicalTrials.gov identifier NCT00535418.

References

    1. Fisher B, Redmond C, Fisher ER, Bauer M, Wolmark N, Wickerham DL, Deutsch M, Montague E, Margolese R, Foster R. Ten-year results of a randomized clinical trial comparing radical mastectomy and total mastectomy with or without radiation. N Engl J Med. 1985;312:674–681.
    1. Silliman RA. What constitutes optimal care for older women with breast cancer? J Clin Oncol. 2003;21:3554–3556. doi: 10.1200/JCO.2003.05.083.
    1. Eiermann W, Paepke S, Appfelstaedt J, Llombart-Cussac A, Eremin J, Vinholes J, Mauriac L, Ellis M, Lassus M, Chaudri-Ross HA, et al. Preoperative treatment of postmenopausal breast cancer patients with letrozole: A randomized double-blind multicenter study. Ann Oncol. 2001;12:1527–1532. doi: 10.1023/A:1013128213451.
    1. Paepke S, Bouterfa H, Wallwiener D, the FEM-D-1 study group A multicenter study of pre-operative treatment with Femara® (Letrozole) for optimal duration of treatment in postmenopausal women with ER and/or PgR positive breast cancer. Breast Cancer Res Treat. 2001;69:290. (Abstract 453).
    1. Semiglazov VF, Semiglazov VV, Ivanov VG, Ziltzova EK, Dashyan GA, Kletzel A, Bozhok AA, Nurgaziev KS, Tzyrlina EV, Berstein LM, Petrov NN. Neoadjuvant endocrine therapy: exemestane (E) vs tamoxifen (T) in postmenopausal ER+ breast cancer patients (T1-4N1-2MO) Breast Cancer Res Treat. 2003;82:S22.
    1. Smith I, Dowsett M, on behalf of the IMPACT Trialists Comparison of anastrozole vs tamoxifen alone and in combination as neoadjuvant treatment of estrogen-receptor positive (ER+) operable breast cancer in postmenopausal women: the IMPACT trial. Breast Cancer Res Treat. 2003;82:S6.
    1. Gazet JC, Ford HT, Coombes RC, Bland JM, Sutcliffe R, Quilliam J, Lowndes S. Prospective randomized trial of tamoxifen vs surgery in elderly patients with breast cancer. Eur J Surg Oncol. 1994;20:207–214.
    1. Mustacchi G, Milani S, Pluchinotta A, De Matteis A, Rubagotti A, Perrota A. Tamoxifen or surgery plus tamoxifen as primary treatment for elderly patients with operable breast cancer: The G.R.E.T.A. Trial. Group for Research on Endocrine Therapy in the Elderly. Anticancer Res. 1994;14:2197–2200.
    1. Robertson JF, Ellis IO, Elston CW, Blamey RW. Mastectomy or tamoxifen as initial therapy for operable breast cancer in elderly patients: 5-year follow-up. Eur J Cancer. 1992;28A:908–910. doi: 10.1016/0959-8049(92)90148-U.
    1. Buzdar A, Howell A. Advances in aromatase inhibition: clinical efficacy and tolerability in the treatment of breast cancer. Clin Cancer Res. 2001;7:2620–2635.
    1. Abrial C, Mouret-Reynier MA, Cure H, Feillel V, Leheurteur M, Lemery S, Le Bouedec G, Durando X, Dauplat J, Chollet P. Neoadjuvant endocrine therapy in breast cancer. Breast. 2006;15:9–19. doi: 10.1016/j.breast.2005.07.009.
    1. Ellis MJ, Coop A, Singh B, Mauriac L, Llombert-Cussac A, Janicke F, Miller WR, Evans DB, Dugan M, Brady C, et al. Letrozole is more effective neoadjuvant endocrine therapy than tamoxifen for ErbB-1- and/or ErbB-2-positive, estrogen receptor-positive primary breast cancer: evidence from a phase III randomized trial. J Clin Oncol. 2001;19:3808–3816.
    1. Mouridsen H, Gershanovich M, Sun Y, Perez-Carrion R, Boni C, Monnier A, Apffelstaedt J, Smith R, Sleeboom HP, Janicke F, et al. Superior efficacy of letrozole versus tamoxifen as first-line therapy for postmenopausal women with advanced breast cancer: results of a phase III study of the International Letrozole Breast Cancer Group. J Clin Oncol. 2001;19:2596–2606.
    1. Paepke S, Jacobs VR, Paepke D, Euler U, Blohmer JU, Warm M, Ohlinger R, Fischer T, Kiechle M, Harbeck N. Critical appraisal of primary systemic endocrine therapy in receptor-positive postmenopausal breast cancer: an update. Onkologie. 2006;29:210–217. doi: 10.1159/000092267.
    1. Dixon JM, Love CD, Bellamy CO, Cameron DA, Leonard RC, Smith H, Miller WR. Letrozole as primary medical therapy for locally advanced and large operable breast cancer. Breast Cancer Res Treat. 2001;66:191–199. doi: 10.1023/A:1010669403283.
    1. Miller WR, Dixon JM, Cameron DA, Anderson TJ. Biological and clinical effects of aromatase inhibitors in neoadjuvant therapy. J Steroid Biochem Mol Biol. 2001;79:103–107. doi: 10.1016/S0960-0760(01)00149-2.
    1. World Health Organization . Handbook for reporting results of cancer treatment WHO Offset Publication No 48. Geneva: WHO; 1979.
    1. Smith IE, Dowsett M. Aromatase inhibitors in breast cancer. N Engl J Med. 2003;348:2431–2442. doi: 10.1056/NEJMra023246.
    1. Paepke S, Tulusan A, Kiesel L, Bastert G, Jaenicke FK, Bouterfa H, Wackwitz B, Wallwiener D. A multi-center study of pre-operative treatment with Letrozole for optimal duration of treatment in postmenopausal women with ER and/or PGR positive breast cancer. Proc Am Soc Clin Oncol. 2003;22:321. (Abstract).
    1. Renshaw L, Murray J, Young O, Cameron D, Miller WR, Dixon JM. Is there an optimal duration of neoadjuvant letrozole therapy? Breast Cancer Res Treat. 2004;88:S36–S37. (Abstract 405).

Source: PubMed

Sponsorer og samarbejdspartnere

Medicinske tilstande

Narkotikainterventioner

3
Abonner